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Abstract
Background: Cognitive problems in people with schizophrenia predict poor functional recovery even with the best
possible rehabilitation opportunities and optimal medication. A psychological treatment known as cognitive remediation
therapy (CRT) aims to improve cognition in neuropsychiatric disorders, with the ultimate goal of improving functional
recovery. Studies suggest that intervening early in the course of the disorder will have the most benefit, so this study will
be based in early intervention services, which treat individuals in the first few years following the onset of the disorder.
The overall aim is to investigate different methods of CRT.
Methods: This is a multicentre, randomised, single-blinded, controlled trial based in early intervention services in National
Health Service Mental Health Trusts in six English research sites. Three different methods of providing CRT
(intensive, group, and independent) will be compared with treatment as usual. We will recruit 720 service users
aged between 16 and 45 over 3 years who have a research diagnosis of non-affective psychosis and will be at
least 3 months from the onset of the first episode of psychosis. The primary outcome measure will be the degree to
which participants have achieved their stated goals using the Goal Attainment Scale. Secondary outcome measures will
include improvements in cognitive function, social function, self-esteem, and clinical symptoms.
Discussion: It has already been established that cognitive remediation improves cognitive function in people with
schizophrenia. Successful implementation in mental health services has the potential to change the recovery trajectory
of individuals with schizophrenia-spectrum disorders. However, the best mode of implementation, in terms of efficacy,
service user and team preference, and cost-effectiveness is still unclear. The CIRCuiTS trial will provide guidance for a
large-scale roll-out of CRT to mental health services where cognitive difficulties impact recovery and resilience.
Trial registration: ISRCTN, ISRCTN14678860, Registered on 6 June 2016.
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Background
Schizophrenia is a relatively common disorder with a
lifetime risk of around 1% [1]. It typically has an onset in
late adolescence or early adulthood, so can derail the
academic, interpersonal and employment achievements
that prepare a person for adult roles and responsibilities
[1]. It is also associated with an average loss of life-span
of up to 20 years [2], poor employment prospects and
difficulty in achieving satisfying social relationships. Poor
prognosis is established soon after illness onset, with
estimates of sustained social and occupational recovery
being only 17–25% in the first 5 years [3]. Although
positive symptoms (delusions and hallucinations) are a
hallmark of a diagnosis of schizophrenia, cognitive dys-
function is apparent prior to the onset of psychosis and
remains unchanged despite symptom remission [4, 5].
Poor cognition in people with a diagnosis of schizophre-
nia is a key predictor of poor functional outcome [6, 7]
and impairments are noticeable in about 96% of all out-
patients [8]. It is cognitive function at psychosis onset,
and not symptom profile or response to treatment, that
most strongly predicts social and occupational function-
ing 4 years later [9]. Cognitive difficulties also limit the
rate of improvement using evidence-based rehabilitation,
so that those who have the most difficulty will gain
least [6]. Interventions that can boost cognition or
maintain cognitive reserve would be beneficial, as these
improvements are likely to have wide-ranging effects
on service outcomes.
Owing to the potential for chronicity and morbidity,
the economic burden of schizophrenia is immense. In
the UK, it was estimated as £19b in 2012, and for each
patient each year as £60k in societal costs and £36k in
public sector costs (Schizophrenia Commission 2012
[10]) with similar figures found in the USA [11]. Much
of the social burden is due to lost employment, housing
and benefits [12]. New UK mental health policies, such
as ‘No health without mental health’ [13], stress the need
for early intervention to make long-lasting differences in
people’s lives. With such a poor prognosis and high costs
as well as personal burden, it is vital to explore whether
new therapies can improve the recovery trajectory and
thus decrease costs. Embedding cognitive treatments
early, as in early intervention services (designed for
clients who undergo intensive case management over
the first 3 years of illness), may confer potentially long-
lasting benefits.
Cognitive remediation therapy (CRT) was developed
to address cognitive problems in people with schizo-
phrenia. The Cognitive Remediation Experts Workshop
in 2012 [14] defined it as ‘an intervention targeting
cognitive deficit using scientific principles of learning
with the ultimate goal of improving functional outcomes’
(p. 1). The largest meta-analysis (> 2000 participants in
40 studies) demonstrated that CRTs provide durable
benefits in global cognition (effect size, 0.45) and func-
tioning (Cohen’s d effect size, 0.42) [15] against any
control group. New evidence and systematic reviews
were taken into consideration by the Scottish Guideline
Network for Healthcare Improvement Scotland [16]
(extending the National Institute for Health and Care
Excellence (NICE) guidelines of 2014 [17]) and CRT is
now recommended in Scotland. Because of this wealth
of evidence, other countries, such as Australia, Italy
and Japan, and the New York State mental health
services now include it in their guidance.
Cognitive remediation experts [14] recommend that
‘the effect on functioning is enhanced when provided in
a context (formal or informal) that provides support and
opportunity for extending everyday functioning’ p. 1.
This is based on evidence that CRT boosted outcomes
in other evidence-based therapies [18, 19]. One study,
based in an early invention for psychosis services, also
demonstrated that CRT can halve the number of cogni-
tive behaviour therapy sessions needed for the same
symptom reduction, reducing costs [19]. Early interven-
tion services provide multimodal therapies, as well as
contact with social and employment services. They
therefore offer formal and informal opportunities for the
translation of gains, as well as the potential to boost
CRT outcome and improve the potential for changing
recovery trajectories and sustaining benefits.
Cognitive remediation studies in younger people dem-
onstrate acceptability and benefit in the short and longer
term for cognitive and functional domains [20–22];
secondary analyses show greater gains for younger par-
ticipants [23, 24]. There is ample evidence of biological
and cognitive effects in schizophrenia, in which loss of
brain grey matter [25, 26] and network disconnectivity
occurs early in the disorder, but also evidence that CRT
offers neuroprotective effects against grey matter loss
[27] and improves brain activation [28]. As CRT has
been shown to be effective for younger people and has
the potential to improve functioning, it may be most
beneficial if interventions are delivered at the earliest
opportunity. There was optimism that early intervention
services would have longer-term benefits but, despite
quick access to multimodal treatments, it has been diffi-
cult to demonstrate that short-term improved outcomes
were durable [29–31], although individual studies show
better results [32]. On the whole, the results are like
those of Bertelsen and colleagues [33] that, irrespective
of receiving early intervention services, 60% of service
users were neither working nor studying 5 years after
psychosis onset. Clearly the current ingredients of
recovery-focused treatments are not achieving their full
potential for later function. This trial has also taken a
recovery-focused approach and highlights those outcomes
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of relevance to an individual. Our primary outcome meas-
ure is, therefore, the important functional goal as chosen
by the participant.
Cognitive remediation therapy is an evidence-based
intervention but what is not obvious is the mode of
implementation necessary and who would benefit most
from different therapeutic modalities. Cognitive remedi-
ation therapies have been provided with high therapist
involvement or very little, and at different intensity
levels. We therefore developed the arms of the trial to
represent the most frequently used implementation
methods. The first is an intensive therapy that has previ-
ously been used by our team [34], which depends on
continuous therapist support. The second arm is one
adopted in many studies, where treatment is provided in
a group with therapeutic support [35]. We have shown
that our current therapy is suitable for such a group-
intervention [36] approach. The final arm is one that
depends on more independent access to therapy and has
been used in several trials with differing effects [37, 38].
The main differences between these implementation
methods is the level of therapist support and therefore
the costs of implementation, with the most independent
being the cheapest. Although the presence or absence of
therapist support did not affect cognitive outcomes [14],
therapist support has been shown to have tangible
effects [39] and service users have positive views about
therapists being present during therapy [40, 41]. Balan-
cing the cost of the service, service user preferences and
outcomes has not been tested as there have been no
direct comparisons using the same cognitive remediation
programme with differing levels of therapist support.
The question of what is the best implementation method
therefore has clinical equipoise. Cognitive remediation
therapies have also generally been tested in single-centre
studies so the effect of differing background services on
outcomes has also not been tested. Therefore, this large,
multicentre trial was developed, with the main aim of
determining the best way of introducing CRT for
psychosis into UK National Health Service (NHS) early
intervention services in order to optimise individual
functional outcomes and costs.
We consulted people with experience of using mental
health services at every stage of trial development as well
as clinicians and carers, mindful of the finding of Ennis
and Wykes [42] that patient involvement is associated
with study success. For example, clinicians do not
routinely introduce the idea of cognitive difficulties at
psychosis onset to service users. To address this sensi-
tive issue, we consulted service users, carers and mental
health clinicians through focus groups and developed
three study leaflets, which were approved by an ethics
committee, to accompany the participant information
sheet. We also consulted the National Institute for Health
Research Biomedical Research Centre Young Person’s
Mental Health Research Advisory group about the design,
wording of the protocol, participant information sheet,
consent form and other promotional material for the trial.
Trial aims and objectives
The aim is to determine the best method of introducing
CRT for psychosis in UK NHS early intervention ser-
vices to optimise individual functional outcomes and
costs. The objectives are to compare three methods of
CRT delivery on: (a) the degree to which participants
have achieved their stated goals using the Goal Attainment
Scale as the primary outcome measure; (b) improvement in
cognition, social function, self-esteem and symptoms (the
secondary outcome measures); (c) cost-effectiveness; )d)
satisfaction of the service users and staff involved in the
implementation.
Methods
Trial design
This is a multicentre, blinded, randomised, controlled
trial conducted in the early intervention services of UK
NHS Mental Health Trusts. Three different methods of
providing CRT (intensive, group or independent) and
treatment as usual within each of six research sites will
be compared on their ability to improve real-world
outcomes. In addition, implementation methods will be
compared on their acceptability to service users, and the
cognitive, clinical and real-world outcomes and cost-
effectiveness, using a net-benefit approach. The site is
designed to compare different services; catchment areas
of the participating trusts range from high-density inner
city to suburban and so cover diverse populations and
different service backgrounds. Outcomes are measured
at 0 (baseline), 15 (post-treatment) and 39 (follow-up)
weeks after randomisation (see Additional file 1).
Trial governance
The oversight of the trial is undertaken by a steering
committee which, in addition to statistical and trial advi-
sors, includes a service user and carer. In addition, an
ECLIPSE service user advisory group meets three times a
year to advise on any problems and to provide feedback
on trial progress. The trial was registered at ISRCTN (ref.:
14678860), a primary clinical trial registry recognised by
the World Health Organization and the International
Committee of Medical Journal Editors. The trial was
reviewed and given a favourable opinion by the
National Research Ethics Service NHS Committee
(Camden and King’s Cross Research Ethical Commit-
tee, ref. 15/LO/1960).
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Participants
Participants will be recruited from NHS early intervention
services across six research sites in England (Birmingham,
Coventry and Warwickshire, East Anglia, North London,
South London, and Sussex).
Inclusion criteria
(a)Attending an early intervention service and at least 3
months from the onset of the first episode of psychosis;
clinical stability, as judged by the clinical team
(b)Aged between 16 and 45
(c)Research diagnosis of non-affective psychosis, i.e.
schizophrenia, schizo-affective or schizophreniform
disorder following assessment
(d)Ability to give informed consent
These entry criteria were developed following discus-
sion with staff, service users and carers to ensure a
pragmatic approach. For example, the requirement for
clinical stability will exclude a proportion of service
users but this will be the approach used in reality to
ensure that individuals can cope with the demands of
the therapy, including regular attendance. It is also an
entry criterion that both staff and service users recom-
mended for the trial. The age criterion is the one
adopted in early intervention services. The decision to
consider individuals as potential participants after 3
months is based on the establishment of individuals
into treatment in early intervention services following
initial stabilisation after the acute episode.
Exclusion criteria
(a)Not able to communicate in English sufficiently to
participate in cognitive testing
(b)Suffering from an underlying organic or neurological
condition affecting cognition, e.g. traumatic brain
injury or seizure disorder
(c)Have a comorbid diagnosis of intellectual disability
At each site, the early intervention services clinicians
will be asked to identify service users with a non-affective
psychosis. Early intervention services clinicians will
approach patients individually to ascertain permission for
the research team to approach. Written consent will be
obtained by trained research workers. After a consent
form is signed, the researchers confirm the diagnosis by
completing the relevant sections of the Mini-International
Neuropsychiatric Interview (sections A ‘Major depressive
episode’, D ‘Manic or hypomanic episode’ and L ‘Psychotic
disorders’) [43]. Trial withdrawal will be recommended by
the early intervention services clinician who provides
treatment as usual. Figure 1 provides the participant flow
chart; the enrolment schedule is provided in Fig. 2.
Allocation and blinding
Therapists use secure email to send a list of (11–15)
consenting and assessed participants to the King’s
Clinical Trials Unit, which allocates each participant
using pre-generated randomisation lists. The rando-
mised allocations are sent back to the therapist by
secure email. The pre-generated randomisation lists are
stored by the King’s Clinical Trials Unit in an access-
restricted electronic folder that is not accessible to any
members of the study team. The therapist informs each of
the participants of their allocated trial arm.
Randomisation is stratified by research site in the
proportion 4:4:3:4 (Group CRT, independent CRT, inten-
sive CRT, treatment as usual) to make efficient use of
therapist resources. Alternative randomisation alloca-
tions will be used if 15 participants cannot be recruited
within the stipulated 12-week recruitment period, with a
minimum block of 11 participants (reducing the propor-
tions in the independent CRT and treatment-as-usual
arms only so as not to break the group design constraint
or reduce the number of participants in the intensive
CRT arm). This flexibility allows more efficient use of
therapist time and resources as the therapist time is
limited and the intensive therapy absorbs a lot of this
resource.
The whole team, apart from the therapists and the
randomisation statistician, are blind to participant group
allocation. Breaches will be recorded; if a breach is to a
research assessor, another research worker will complete
the assessment. An audit of the quality of the blinding
will be conducted at the end of the study.
Participant data are entered online into a secure elec-
tronic data capture system hosted by the King’s Clinical
Trials Unit separately from treatment allocation data.
Data quality and audit are regularly tested prior to and
after data entry. Analysis scripts are agreed and finalised
by the senior statistician prior to unblinding.
Interventions
The CRT interventions (intensive, group, independent)
will be carried-out using the CIRCuiTS computerised
cognitive remediation programme; CIRCuiTS is based
on a successful paper-and-pencil therapy and was devel-
oped with service users and therapists to increase
engagement with younger clients who value compu-
terised therapy [44, 45]. The three CRT delivery modes
will differ in the associated hours of therapist contact
but all participants will be offered 42 treatment hours. A
treatment-as-usual arm will be evaluated, as CRT is not
yet recommended in England by NICE; this will allow us
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to assess cost-effectiveness. All trial participants will
continue to receive standard care throughout the trial.
Therapy will be delivered at each site by an experi-
enced assistant psychologist trained in CRT at the trial
centre and supervised centrally on a weekly basis. Each
therapist will provide all three types of CRT over the
therapy period.
(a)Intensive CRT. Participants will receive 10.5 weeks
of twice weekly therapy, up to 42 h in total, with
sessions lasting between 60 and 180 min, split into
three parts: (1) 20–60 min of CRT with a therapist;
(2) 20–60 min of in-vivo transfer work (i.e. putting
CRT strategies into real life) with a therapist; (3) 20–60
min of independent CRT, set up by the therapist
on-site, or off-site in the service user’s own time.
(b)Group CRT. Participants randomised in this arm
will be offered 14 weeks of thrice weekly group
therapy (up to 42 h of CRT). Group sessions will
last up to 90 min, with attendance for at least 20
min considered as a completed session. Groups have
closed membership, with four participants per group
Fig. 1 Participant flow chart. CRT, cognitive remediation therapy; PIS, patient information sheet; TAU, treatment as usual
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and one therapist. The sessions will begin and end
with group activities, relating to goal setting and
metacognition. During the rest of the session, service
users will work independently on CIRCuiTS tasks,
with the therapist offering help and support on an
as-needed basis.
(c)Independent CRT. Participants will receive one
individual session with the therapist for orientation
followed by up to 41 sessions when they will work
independently (up to 42 h of CRT in total). To support
the independent sessions, the therapist will offer
telephone contact or attendance at drop-in sessions
on an as-needed basis to address any questions or
problems (but not exceeding 1 h contact time per
fortnight). A session will be considered ‘valid’ if it
lasts a minimum of 20 min.
(d)Treatment as usual. This will be the standard input
offered by the treating team without restrictions.
Standard care involves clinical contact with the team
on a daily, weekly or monthly basis depending on
recovery. It also involves opportunities to be
involved in educational or employment
programmes, other psychological therapies, e.g.
cognitive behaviour therapy for psychosis and
medical treatments, including drug therapies.
Participants randomised to the treatment-as-usual
group will not receive CRT therapy.
Outcomes
The primary outcome measure of the trial is the degree
to which participants achieve their personal goals, as
measured by the Goal Attainment Scale [46, 47] 15 and
39 weeks after randomisation. The Goal Attainment
Scale is a method of scoring the extent to which partici-
pant’s individual goals (set at baseline) are achieved
during the intervention. In effect, participants each have
their own outcome measure but this is scored in a stan-
dardised way to allow statistical analysis. The goals are
individually identified to suit the participant, and the
levels are individually set around their current and
Enrolment
Pre-therapy 
assessments
Allocation Intervention
Post-therapy 
assessment
6-month follow-up
TIMEPOINT −T2 −T1 0 T1 T2
ENROLMENT
Eligibility form x
Informed consent x
Mini International 
Neuropsychiatric 
Interview (MINI)
x
RANDOMISATION
Allocation x
INTERVENTIONS
Intensive CRT x
Group CRT x
Independent CRT x
TAU condition 
ASSESSMENTS
Goal Attainment Scale x                               
(goals set)
x                          
(outcome rated)
x
(outcome rated)
The Time Use Survey x x x
The Client Service 
Receipt Inventory
x x x
EQ-5D-5L x x x
Rosenberg Self Esteem 
Scale
x x x
WTAR x
WASI II x
CANTAB tasks x x x
Computerised 
Wisconsin Card Sorting 
Task (WCST)
x x x
Rey Auditory Verbal 
Learning Test
x x x
Rey Osterrieth Complex 
Figure
x x x
Digit Span x x x
Fig. 2 Schedule of enrolment, interventions and assessments. CANTAB, Cambridge Neuropsychological Test Automated Battery; CRT, cognitive
remediation therapy; EQ-5D-5L, EuroQOL five dimensions questionnaire; MINI, Mini-International Neuropsychiatric Interview; TAU, treatment as usual;
WASI II, Wechsler Abbreviated Scale of Intelligence – Second Edition; WCST, Wisconsin Card Sorting Task; WTAR, Wechsler Test of Adult Reading
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expected levels of performance. The Goal Attainment
Scale has been adopted in several studies of psychosocial
interventions in mental health [48, 49]. It has been
shown to be a reliable method of rating behaviours
by self-report, which is comparable, but not identical,
to informant and researcher reports, and has wide
use in studies of cognitive rehabilitation and in clin-
ical practice [50–52].
The secondary outcome measures, some of which are
used in the cost-effectiveness analysis, are: (a) social and
occupational functioning, as measured by the Time Use
Survey [53] and the EuroQOL five dimensions question-
naire [54]; (b) use of services, as measured by the Client
Service Receipt Inventory [55]; (c) self-esteem, as measured
by the Rosenberg Self-Esteem Scale [56]; and (d) cognition,
as measured by the Cambridge Neuropsychological Test
Automated Battery (which includes the following tests:
Reaction Time, One-Touch Stockings of Cambridge,
Paired-Associates Learning, Attention Switching Task,
Rapid Visual Information Processing, Spatial Working
Memory and Emotion Recognition Task) and supple-
mented by the Computerized Wisconsin Card Sorting
Task [57], Rey Auditory Verbal Learning Test [58], Rey
Osterrieth Complex Figure [59] and Digit Span forwards
and back test [60]. We also collect some background data
to investigate treatment mechanisms, including the
Wechsler Abbreviated Scale of Intelligence [61] and meta-
cognition measures. A description of these outcomes is
presented in Additional file 2: Table S1.
Data are collected by trained research assistants, whose
reliability is assessed regularly. Consistency between sites
is achieved by regular review by members of the manage-
ment and research teams as well as data quality checks at
the site and by audit through the trial statistician.
Measurement
Power
We have the capacity to recruit 900 patients (from 1500
patients attending 10 services for 3 years) and have
allowed for a 20% drop-out pre-randomisation. Using a
design with parallel arms of equal size, with 180 patients
per arm, provides approximately 80% power for a simple
group effect size difference of 0.3. This increases to 91%
for outcomes that correlate 0.5 with baseline (both
calculated using sampsi in Stata).
Freidlin et al. [62] suggest no great advantage in
accounting for multiple testing in a multi-arm trial, and
also that the advantages of a larger treatment-as-usual
arm are more slight than commonly assumed. Inter-
action among patients in group delivery is very slight so
no allowance for clustering was thought necessary.
The power calculation is based on arms of equal size;
the difference in power as a result of the unequal
allocation is likely to be small as the use of modestly un-
equal randomisation ratios only very slightly reduces the
power of a study [63].
Analysis
The primary outcome measure will be group differ-
ences in Goal Attainment Scale T-score [47] at 15 weeks
post-randomisation, tested using an analysis of covari-
ance (ANCOVA) model co-varying for Goal Attainment
Scale T-score at baseline and adjusting for site as a fixed
effect. Pairwise comparisons will be conducted between
each of the CRT arms and treatment as usual, with
significance and confidence intervals calculated using
nominal values of p. Data will be analysed under intention-
to-treat assumptions. Treatment effects for secondary
outcomes will be analysed in a similar way. For the primary
outcome, given the probable differences in treatment
uptake (adherence), local average or complier average treat-
ment effects compared with treatment as usual will also be
estimated. Using assigned arm as an instrumental variable,
all arms will be examined together to estimate the effect of
hours of active CRT. On an assumption of a common
per-hour effect across arms, some residual information
will be available to estimate residual direct effects of
treatment mode.
The cost-effectiveness analysis will be conducted from
the perspectives of health and social care and society (in-
cluding informal care, lost employment). Service use,
collected using the Client Service Receipt Inventory, will
be combined with appropriate unit cost information [64]
and added to the intervention costs. Costs will be
compared between groups using bootstrapped regression
models to address the probable skewed distribution.
Cost-effectiveness will be assessed by combining costs
and outcome measures (primary outcome measure and
quality-adjusted life years) in the form of incremental
cost-effectiveness ratios.
If one arm has lower costs and better outcomes than
another, it will be ‘dominant’. However, there will be
uncertainty around the estimates of incremental costs
and outcomes; this will be explored using cost-
effectiveness planes and cost-effectiveness acceptability
curves. The cost-effectiveness planes will be produced
by generating and plotting (via bootstrapped regression
models) 1000 incremental cost–outcome pairs. This will
allow us to determine the probability that each arm has
better outcomes and higher costs, better outcomes and
lower costs, worse outcomes and lower costs, or worse
outcomes and higher costs than the comparator. Cost-
effectiveness acceptability curves will be generated using
the net-benefit approach, whereby the incremental gain
in quality-adjusted life years is multiplied by a range of
threshold values for a quality-adjusted life year (includ-
ing those used by NICE) and subtracting the incremental
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cost. This will be performed on 1000 bootstrapped
incremental cost–outcome pairs and the proportion that
are above zero will indicate that that one arm is more
cost-effective than another. Sensitivity analyses will be
conducted by varying key cost parameters. In particular,
we will increase or decrease the intervention cost by
10%, 25% and 50% and use alternative methods for valu-
ing informal care (e.g. minimum wage, unit cost of a
homecare worker).
Interim analysis Given that CRT is known to be effect-
ive, we want to ensure that we do not adopt all four trial
arms if one treatment arm provides little benefit
compared with the remainder, so we will carry out an
interim intention-to-treat analysis. This will be under-
taken by the health economist, using data from the first
195 patients (using the post-therapy data at 15 weeks
post-randomisation). This analysis may result in one of
the trial arms being closed, with an immediate impact
on the randomisation of the next patients.
The decision to drop an arm will be taken by an inde-
pendent data monitoring committee and will depend on
the resultant cost of therapy and other services and goal
attainment. The costs will include direct therapy inputs
and other services derived from the Client Service
Receipt Inventory.
The direct therapy costs will be calculated from data
on the number and length of sessions, number of
attendees (for group therapy) and unit costs, based on
staff grade and overheads. Cost-effectiveness planes will
be generated by plotting the 1000 incremental cost–out-
come combinations for each pair of comparators. This
will tell us the probability that one therapy has (i) lower
costs and better outcomes, (ii) lower costs and worse
outcomes, (iii) higher costs and better outcomes, or (iv)
higher costs and better outcomes than a comparator.
Governance and monitoring
The trial is sponsored by King’s College London, over-
seen by a National Institute for Health Research (NIHR)
appointed ECLIPSE program steering committee, to
which the trial’s independent data monitoring committee
report. All members of the data monitoring committee
are independent of the trial (are not involved with the
trial in any other way and do not have competing inter-
ests that could impact the trial). The membership of all
the committees can be found in Additional file 2:
Table S2. The data monitoring committee is the only
body involved in the trial that has access to the
unblinded comparative data. It will receive and review
the progress and accruing data of the trial and provide
advice on the conduct of the trial to the trial steering
committee. The role of its members is to monitor
these data and make recommendations to the program
steering committee on whether there are any ethical
or safety reasons why the trial should not continue.
Further details can be found in the data monitoring
committee charter, which is based on DAMOCLES
study group guidance [65]. Adverse events are reviewed
by local principle investigators and stored locally. Serious
adverse events are reported (emailed) within one working
day to the local principle investigator and trial co-ordin-
ator using password-protected forms. All serious adverse
events are reviewed by a chief investigator to make a deci-
sion on whether or not they are definitely, possibly, or not
related to the study intervention and whether they are ex-
pected or unexpected. All serious adverse events are
anonymised and sent to a designated member of the data
monitoring committee for their decision on whether they
must be reported to the research ethical committee.
Discussion
Service user involvement
Service user involvement is an integral part of this study.
Service users not only contributed to the study design but
have also helped us develop the information sheets and
consent forms and the publicity for the study, as well as
advising us on how to approach potential participants. A
service user and carer are also part of our steering
committee. However, we have also chosen to meet our
service user advisory group separately so that we can
explain in more detail the issues we face and what our
potential solutions might be. They can then provide advice
that is not under time pressure or in the context of a large
body of academics who may speak in jargon. This method
of involvement has been suggested as important to ensure
that service users feel they can provide worthwhile feed-
back [66]. Regular meetings are held to describe the
recruitment, challenges and successes and the group is
asked to advise on specific issues. The decisions of the
user advisory group are then implemented and the
minutes are available at meetings of the steering commit-
tee. Following advice on the effectiveness of user involve-
ment [67, 68], we will ensure that our user advisory group
provides value to our whole research programme by inter-
viewing a sample of investigators each year to uncover
and resolve any problems between the user group and the
team. We will also ask the service user advisors to provide
anonymous feedback on whether they think there are
issues that have not been resolved satisfactorily or advice
they feel that we ignored.
Main challenges
The challenges fall into three areas: a changing context
in the NHS; the availability of resources within teams;
and block randomisation. Early intervention services
have changed since the study was designed, as they now
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have specified waiting times and follow new NICE guid-
ance on therapy packages. Both changes have affected
how referrals are managed within teams. To overcome
the new pressures, we will work closely with the clinical
teams, team managers and care coordinators to ensure
that the trial is not adding to these pressures. First, a
full-time cognitive remediation therapist will be included
in the early intervention team to provide early interven-
tion staff an opportunity to refer their clients to CRT
who might be on a waiting list for other therapy. Second,
researchers will assist early intervention staff with risk-
assessment reports (e.g. symptom assessments) and
share a brief report on participant cognitive measures
with the clinical teams, which will help them in their
care programme approach for each individual, irrespect-
ive of whether they are involved in active therapy.
Detailed cognitive assessments are usually not available
in early intervention services, so this will be a benefit of
choosing to take part in the trial.
Resources are always a difficulty, e.g. there may be a
lack of suitable therapy rooms for CRT in some services,
and we aim to help teams locate finance to re-use some
unfurnished rooms. As CRT is not in NICE guidance,
there is also a lack of experienced senior therapists who
can provide specific supervision to more junior staff
within a trust. We have responded by employing a
senior clinical psychologist to offer this additional sup-
port across the sites and ensure continuity over the trial.
We developed our original block randomisation so
that we could use the therapy resources as efficiently as
possible and so blocks were defined as 15 participants.
However, we potentially waste therapy resources with
slow participant acquisition. Hence, we changed the
blocks so that in some circumstances we can reduce the
number of individuals who can be randomised. As with
all trials there is a need to ensure blind assessment so
we have also trained additional staff from each of the
sites to provide extra support with some research proce-
dures that might break the blind, e.g. inspecting clinical
notes, and we will provide alternative raters in the case
of any unblinding.
Participant engagement and dissemination
Relevant research information will be available on the web-
site, which is currently being developed (especially designed
with participants in mind), as well as other social media (i.e.
Twitter). This website will host presentations and peer-
reviewed journal articles as they are produced to ensure ac-
cessibility. We will share our findings with our participants
and participating teams through this method and also by
sending newsletters at regular intervals to update them on
the progress of the projects. Following advice from our user
advisory group, participants will receive Christmas cards
along with other promotional materials.
Providing advice to the NHS
We are mindful that advice on implementation needs to
come from different perspectives. Our three implemen-
tation models vary by therapist input and we will there-
fore have some detail on the effects on our key outcome
variable, which is defined from the participants’ perspec-
tive – their goals as measured by the Goal Attainment
Scale. But this is not all we will be measuring. We have
the perspective of the service user participants on satis-
faction with therapy and the method of provision,
including therapy drop-out and the number of sessions
received. We are collecting staff views so that we know
what they consider appropriate levels of commitment
and resource, as well as the organisational facilitators
and barriers. We will include a provider perspective
through the costs and cost-effectiveness of the different
methods of providing therapy. All these perspectives will
allow us to provide a balanced view of the different
intervention methods so as to optimise their effects.
As well as a comprehensive overall plan for the best
implementation method, our data will also allow us to
discover whether therapy might need to be tailored to
different individuals to provide the best effect. We will
therefore investigate whether individual characteristics
can predict larger or smaller benefits and, importantly,
whether therapy might have a negative effect in some
people. We will also investigate whether organisational
factors, such as staff resources and background treat-
ments, might affect successful CRT implementation.
All this information will allow: (i) policy makers to
plan for this treatment; (ii) individual teams to under-
stand what is required before and during implementa-
tion; and (iii) service users to receive the best
individualised care to improve their recovery potential.
Another of our work packages involves producing and
evaluating an online training resource for this form of
cognitive remediation. Together with the information on
tailoring, this trial will allow smooth roll-out of the ther-
apy into NHS services. Finally, the ECLIPSE programme
will provide an implementation guide using the best
available data.
Trial status
Research protocol, version 1.3, 1 March 2017.
Recruitment start date, 1 June 2017; predicted recruit-
ment end date, 1 January 2020.
Additional files
Additional file 1: SPIRIT 2013 checklist. (DOCX 41 kb)
Additional file 2: Supplemental information. Table S1: Description of
measures; Table S2: Membership of committees; Participant information
sheet; Consent form. (DOCX 978 kb)
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